Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.

Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, Holmberg LH, Tutt AN, Pinder SE.

Mod Pathol. 2013 Jul;26(7):955-66. doi: 10.1038/modpathol.2012.244. Epub 2013 Feb 8.

2.

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.

PMID:
19390427
3.

Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.

Thike AA, Yong-Zheng Chong L, Cheok PY, Li HH, Wai-Cheong Yip G, Huat Bay B, Tse GM, Iqbal J, Tan PH.

Mod Pathol. 2014 Mar;27(3):352-60. doi: 10.1038/modpathol.2013.145. Epub 2013 Aug 9.

4.

Potential prognostic tumor biomarkers in triple-negative breast carcinoma.

Peng Y.

Beijing Da Xue Xue Bao. 2012 Oct 18;44(5):666-72. Review.

5.

Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women.

Esnakula AK, Ricks-Santi L, Kwagyan J, Kanaan YM, DeWitty RL, Wilson LL, Gold B, Frederick WA, Naab TJ.

J Clin Pathol. 2014 Feb;67(2):153-60. doi: 10.1136/jclinpath-2013-201698. Epub 2013 Aug 28.

PMID:
23986556
6.

Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.

Wu YM, Hu W, Wang Y, Wang N, Gao L, Chen ZZ, Zheng WQ.

Breast Cancer Res Treat. 2013 Aug;141(1):23-32. doi: 10.1007/s10549-013-2664-1. Epub 2013 Aug 10.

PMID:
23933801
7.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

9.

P-cadherin and vimentin are useful basal markers in breast cancers.

Tsang JY, Au SK, Ni YB, Shao MM, Siu WM, Hui SW, Chan SK, Chan KW, Kwok YK, Chan KF, Tse GM.

Hum Pathol. 2013 Dec;44(12):2782-91. doi: 10.1016/j.humpath.2013.07.029. Epub 2013 Oct 16.

PMID:
24139214
10.

Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.

Ortiz-Martínez F, Perez-Balaguer A, Ciprián D, Andrés L, Ponce J, Adrover E, Sánchez-Payá J, Aranda FI, Lerma E, Peiró G.

Hum Pathol. 2014 Mar;45(3):504-12. doi: 10.1016/j.humpath.2013.10.015. Epub 2013 Oct 30.

PMID:
24440093
11.

Clinical significance of basal-like subtype in triple-negative breast cancer.

Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H.

Breast Cancer. 2009;16(4):260-7. doi: 10.1007/s12282-009-0150-8. Epub 2009 Aug 22.

PMID:
19701681
12.

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.

Hum Pathol. 2009 Nov;40(11):1528-33. doi: 10.1016/j.humpath.2009.05.005. Epub 2009 Aug 19.

PMID:
19695680
13.

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.

Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ.

Breast Cancer Res. 2007;9(5):R65.

14.

Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer.

Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH.

Mod Pathol. 2010 Jan;23(1):123-33. doi: 10.1038/modpathol.2009.145. Epub 2009 Oct 23.

15.
16.

Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.

Zhu X, Shan L, Wang F, Wang J, Wang F, Shen G, Liu X, Wang B, Yuan Y, Ying J, Yang H.

Breast Cancer Res Treat. 2015 Apr;150(3):479-86. doi: 10.1007/s10549-015-3338-y. Epub 2015 Mar 18.

PMID:
25783183
17.

Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.

Nassar A, Sussman ZM, Lawson D, Cohen C.

Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.

PMID:
22882580
18.

Expression of Basal-like Biomarkers in Triple Negative Invasive Breast Carcinoma in Puerto Rico.

Agosto-Arroyo E, Climent C, Vélez R, Nazario CM, Díaz MV.

P R Health Sci J. 2015 Jun;34(2):89-92.

PMID:
26061059
19.

Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.

Niwińska A, Olszewski W, Murawska M, Pogoda K.

J Neurooncol. 2011 Dec;105(3):547-53. doi: 10.1007/s11060-011-0616-3. Epub 2011 Jun 9.

20.

A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.

Cakir A, Gonul II, Uluoglu O.

Diagn Pathol. 2012 Oct 20;7:145. doi: 10.1186/1746-1596-7-145.

Supplemental Content

Support Center